Andrew Cunningham
Directeur Technique/Scientifique/R&D chez CALCIMEDICA, INC.
Profil
Andrew Cunningham is currently the Senior Vice President-Clinical Development at CalciMedica, Inc. He previously worked as the Medical Director at Takeda Pharmaceutical Co., Ltd.
from 2017 to 2018, and as the Medical Director at Genzyme Therapeutics Ltd.
from 2012 to 2014.
He also served as the Vice President-Clinical Development at Reata Pharmaceuticals, Inc. from 2018 to 2021, and as the Head-Neurodegenerative at Taysha Gene Therapies, Inc. from 2021 to 2022.
Dr. Cunningham obtained his undergraduate degree and an MBA from University College Dublin.
Postes actifs de Andrew Cunningham
| Sociétés | Poste | Début |
|---|---|---|
| CALCIMEDICA, INC. | Directeur Technique/Scientifique/R&D | 23/05/2023 |
Anciens postes connus de Andrew Cunningham
| Sociétés | Poste | Fin |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Corporate Officer/Principal | 01/04/2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01/07/2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01/06/2014 |
Formation de Andrew Cunningham
| University College Dublin | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CALCIMEDICA, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Entreprise privées | 2 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
